Biological Assembly 1  

 3D View: Structure | Electron Density | Ligand Interaction

Standalone Viewers  
Protein Workshop | Ligand Explorer

Global Symmetry: Asymmetric - C1 
Global Stoichiometry: Monomer - A 

Biological assembly 1 assigned by authors and generated by PISA (software)

Macromolecule Content

• Total Structure Weight: 51500.55 
• Atom Count: 3539 
• Residue Count: 455 
• Unique protein chains: 1

4MLH

Human Glucokinase in Complex with a Novel Amino Thiazole Allosteric Activator

• DOI: 10.2210/pdb4MLH/pdb

• Classification: TRANSFERASE/TRANSFERASE ACTIVATOR
• Organism(s): Homo sapiens
• Expression System: Escherichia coli BL21(DE3)


• Deposited: 2013-09-06 Released: 2013-09-25 
• Deposition Author(s): Voegtli, W.C.

---

Experimental Data Snapshot

• Method: X-RAY DIFFRACTION
• Resolution: 2.9 Å
• R-Value Free: 0.282 
• R-Value Work: 0.222 

Literature

Identification of a New Class of Glucokinase Activators through Structure-Based Design.

Hinklin, R.J., Boyd, S.A., Chicarelli, M.J., Condroski, K.R., Dewolf, W.E., Lee, P.A., Lee, W., Singh, A., Thomas, L., Voegtli, W.C., Williams, L., Aicher, T.D.

(2013) J.Med.Chem. 56: 7669-7678

• PubMed: 24015910 
• DOI: 10.1021/jm401116k
• Primary Citation of Related Structures:  
  4MLE


• PubMed Abstract: 
  

Glucose flux through glucokinase (GK) controls insulin release from the pancreas in response to high glucose concentrations. Glucose flux through GK also contributes to reducing hepatic glucose output. Because many individuals with type 2 diabetes appear to have an inadequacy or defect in one or both of these processes, compounds that can activate GK may serve as effective treatments for type 2 diabetes. Herein we report the identification and initial optimization of a novel series of allosteric glucokinase activators (GKAs). We discovered an initial thiazolylamino pyridine-based hit that was optimized using a structure-based design strategy and identified 26 as an early lead. Compound 26 demonstrated a good balance of in vitro potency and enzyme kinetic parameters and demonstrated blood glucose reductions in oral glucose tolerance tests in both C57BL/6J mice and high-fat fed Zucker diabetic fatty rats.

---

Organizational Affiliation: 

Array BioPharma , 3200 Walnut Street, Boulder, Colorado 80301, United States.

Macromolecules

Find similar proteins by: Sequence  |  Structure

Entity ID: 1
Molecule	Chains	Sequence Length	Organism	Details
Glucokinase	A	455	Homo sapiens	Mutation(s): 0  Gene Names: GCK EC: 2.7.1.1
Find proteins for P35557 (Homo sapiens) Go to Gene View: GCK Go to UniProtKB:  P35557

Small Molecules

Ligands 2 Unique
ID	Chains	Name / Formula / InChI Key	2D Diagram & Interactions
VO2	A	3-(benzyloxy)-5-methyl-N-(4-methyl-1,3-thiazol-2-yl)pyridin-2-amine C17 H17 N3 O S QFOFZZJJRFMLKB-UHFFFAOYSA-N
GLC	A	ALPHA-D-GLUCOSE C6 H12 O6 WQZGKKKJIJFFOK-DVKNGEFBSA-N

External Ligand Annotations
ID	Binding Affinity (Sequence Identity %)
VO2	EC50: 2640 nM (100) BINDINGDB

Experimental Data & Validation

Experimental Data

• Method: X-RAY DIFFRACTION
• Resolution: 2.9 Å
• R-Value Free: 0.282 
• R-Value Work: 0.222 
• Space Group: P 6₅ 2 2

Unit Cell:

Length (Å)	Angle (°)
a = 78.770	α = 90.00
b = 78.770	β = 90.00
c = 319.620	γ = 120.00

Software Package:

Software Name	Purpose
CNS	refinement
MOSFLM	data reduction
CrystalClear	data collection
CNS	phasing
SCALA	data scaling

Structure Validation

Entry History 

Deposition Data

• Deposited Date: 2013-09-06 
• Released Date: 2013-09-25 
• Deposition Author(s): Voegtli, W.C.

Revision History 

• Version 1.0: 2013-09-25
  Type: Initial release
• Version 1.1: 2013-10-23
  Type: Database references